Phase II Double-Blinded Placebo-Controlled Study Of Bevacizumab With Or Without Amg 386 In Patients With Recurrent Glioblastoma Or Gliosarcoma.
Posted Date: May 15, 2019
- Investigator: Kevin Redmond
- Type of Study: Drug
This study will find effects of Bevacizumab with or without AMG 386 on brain tumors. The FDA has approved bevacizumab for recurrent GBM. However, bevacizumab alone has only modestly improved overall survival. For this reason, other drugs, such as AMG 386, are being evaluated. AMG 386 is investigatio
Criteria:
Eligible Patients Must Have A Brain Tumor, Called A Glioblastoma Or Gliosarcoma, Which Has Become Wo
Keywords:
Brain Cancer, Brain Tumor, Gbm, Neuro-Oncology, R1122
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu